Huadong Medicine Co., Ltd. (华东医药股份有限公司)

Huadong Medicine Co., Ltd. (SZSE: 000963), through its subsidiary Sinclair Pharma, represents China's most ambitious global medical aesthetics platform. With total revenue of ¥436.12 billion (+4.07%) and aesthetics contributing ¥15.68 billion in the first three quarters of 2025 (+113.7% YoY), Huadong has assembled 38 premium aesthetic products spanning injectables, devices, and skincare.

1. Financial & Market Performance

Huadong Medicine reported total 2025 revenue of ¥436.12 billion (+4.07% YoY). The aesthetics division emerged as the company's fastest-growing segment, generating ¥15.68 billion in just the first three quarters of 2025 — an extraordinary 113.7% year-over-year increase. This explosive growth reflects the rapid expansion of China's medical aesthetics market and Huadong's successful execution of its "Global R&D + China Commercialization" strategy. The company invested ¥2.982 billion in R&D (6.83% of pharmaceutical revenue), funding programs across regenerative aesthetics, recombinant collagen, and weight management. The company is evaluating a potential separate listing of its aesthetics division.

2. Manufacturing & Supply Chain

Huadong Medicine operates a multi-site global manufacturing network: Sinclair's European facilities in the UK and Netherlands provide GMP-certified injectable production, the planned Netherlands collagen facility will produce recombinant collagen for aesthetic and medical applications, and Huadong's Hangzhou base manages domestic pharmaceutical manufacturing. The company's "Made in Europe for China" positioning — products manufactured in EU facilities and marketed in China — resonates with Chinese consumer preferences for European quality. Huadong's pharmaceutical sales infrastructure of 6,000+ medical representatives provides unmatched commercial reach in the Chinese market.

3. Key Developments & Strategic Outlook

Huadong Medicine's outlook is exceptionally positive, driven by continued explosive Chinese aesthetics market growth, the rollout of new Sinclair products including next-generation biostimulators and toxin candidates, and strategic expansion into GLP-1 weight management therapeutics. The company is leveraging its massive Chinese commercial infrastructure to cross-sell aesthetics products through hospital and clinic channels. While US-China geopolitical tensions present regulatory risks, Huadong's ownership of European manufacturing infrastructure through Sinclair provides strategic insulation. As China's most aggressive global aesthetics consolidator, Huadong Medicine / Sinclair is fundamentally reshaping competitive dynamics across the entire medical aesthetics value chain.